Home / Market News / $MIST

$MIST news and market catalysts

The 9 most recent market catalysts affecting $MIST, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 1 high impact 6 bullish 2 bearish Pharmaceuticals
Nov 13, 2026 Corporate Catalyst Bullish Impact 75
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures
Milestone Pharmaceuticals announced its Q3 2026 financial results and simultaneously revealed cost-efficiency measures. This move is significant as it directly addresses the compan…
Nov 3, 2026 Corporate Catalyst Bullish Impact 75
Milestone Pharmaceuticals Announces Positive Data for CARDAMYST in Post-Ablation PSVT Patients
Milestone Pharmaceuticals reported new clinical data for its FDA-approved drug, CARDAMYST, demonstrating its effectiveness in a specific patient population: those experiencing recu…
Oct 9, 2026 Corporate Catalyst Bullish Impact 65
Milestone Pharmaceuticals Announces First European Patient Enrolled In Phase 3 Trial Of Etripamil For Atrial Fibrillation With Rapid Heart Rate
The enrollment of the first European patient in a Phase 3 trial is a crucial step for Milestone Pharmaceuticals (MIST). Phase 3 trials are the final stage before regulatory submiss…
Sep 24, 2026 Corporate Catalyst Bullish Impact 65
Milestone Pharmaceuticals Enrolls First Canadian Patient In Phase 3 Trial Of Etripamil For AFib With Rapid Heart Rate
This headline represents a moderate corporate catalyst for Milestone Pharmaceuticals. Successful progression through Phase 3 trials and eventual market approval for Etripamil would…
Sep 3, 2026 Corporate Catalyst Bullish Impact 75
Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults
Milestone Pharmaceuticals (MIST) announced a significant regulatory win with the NMPA approval of its etripamil nasal spray in China for Paroxysmal Supraventricular Tachycardia (PS…
Aug 21, 2026 Corporate Catalyst Bullish Impact 75
Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular Rate
The initiation of a Phase 3 trial is a critical milestone for any pharmaceutical company, as it's the final stage before seeking regulatory approval. For Milestone Pharmaceuticals …
Aug 20, 2026 Corporate Catalyst Neutral Impact 55
Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3
Cantor Fitzgerald's initiation of coverage on Milestone Pharmaceuticals with an 'Overweight' rating and a $3 price target is a positive development for the company. This signals th…
Aug 12, 2026 Corporate Catalyst Bearish Impact 75
Milestone Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
The headline directly points to a corporate catalyst for Milestone Pharmaceuticals (MIST), as their Q2 financial results fell short of expectations. This is a significant event for…
Aug 12, 2026 Corporate Catalyst Bearish Impact 92
Milestone Pharmaceuticals Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $559.000K Miss $816.667K Estimate
Milestone Pharmaceuticals (MIST) announced Q2 earnings that significantly missed analyst expectations for both EPS and sales. The reported loss of $(0.21) per share was worse than …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.